Alimera Sciences leads with $31.8 million in second round.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Alimera Sciences
|
$31.8 million
|
Venrock Associates |
The money goes to develop Alimera Sciences' retinal portfolio, including Medidur, the company's Phase III-stage treatment for diabetic macular edema. |
|
CeNeRx BioPharma
|
$18.5 million
|
Perseus-Soros BioPharmaceutical Fund |
CeNeRx is acquiring and developing early-stage compounds for applications to treat central nervous system diseases. |
|
Antisense Pharma
|
$18 million
|
German MIG funds |
Antisense is using antisense technology to develop targeted anticancer drugs. |
|
Inotek Pharmaceuticals
|
$10 million (second tranche)
|
Caisse de depot et placement du Quebec |
The money will be used to advance its clinical pipeline and reach some significant clinical milestones within "a short period of time." |
|
Advanced BioHealing
|
$8 million
|
Canaan Partners and Wheatley Partners |
The Series B funds will finance ABH's clinical trial to study Celaderm for accelerating healing in partial-thickness burns, enable manufacturing scale-up and develop a marketing team. |